FTC: Using REMS to block generic sample access may violate antitrust laws
This article was originally published in Scrip
The Generic Pharmaceutical Association (GPhA), which lately has been on the opposing side of the US Federal Trade Commission (FTC), gave the agency a big pat on the back on 13 March after the government watchdog declared that a brand-name firm's refusal to sell drug samples to potential generic competitors may violate US antitrust laws.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.